Pfizer names next CEO as Read retires

Ian Read’s tenure has had plenty of ups and downs, and undoubtedly one of his biggest challenges was overcoming the patent expiry of its mega-blockbuster Lipitor in November 2011. ... Pfizer slipped down the rankings in the years following the loss of

Using social data to see patients more clearly

Drugs and databases analysed. The study focused on two drugs, aspirin and Lipitor, that had a relatively high prevalence among the ADR reports in both the clinical and the social media ... In both data sets, musculoskeletal pain and cramps were among the

Pharma set for a strong 2015 as drug sales jump

Pfizer was in fact the hardest hit, with its once $13bn a year statin Lipitor (atorvastatin) losing its patents in 2011/12, with sales falling by $10bn in just two years.

Pfizer maintains lead in top CNS drug sales - just

It is also now Pfizer's top-selling medicine after the 2012 patent expiry of its once £13bn a year statin Lipitor (atorvastatin).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]